Tonix Pharmaceuticals Holding Corp
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 59.5% | 62.6% | 66.9% | 152.5% | 55.1% | 45.8% | 38.8% | 163.8% | 41.6% | 28.7% | 31.0% | 5.2% | 19.8% | |
| 40.5% | 37.4% | 33.1% | -52.5% | 44.9% | 54.2% | 61.2% | -63.8% | 58.4% | 71.3% | 69.0% | 94.8% | 80.2% | |
| 527.7% | 453.0% | 518.3% | 439.2% | 323.0% | 321.3% | 306.1% | 541.5% | 282.3% | 314.3% | 264.8% | 143.4% | 219.4% | |
| 218.4% | 307.5% | 375.1% | 339.8% | 273.1% | 131.7% | 416.0% | 810.9% | 781.2% | 488.1% | 416.2% | 265.5% | 400.6% | |
| 746.1% | 823.2% | 893.4% | 779.0% | 596.1% | 924.8% | 722.1% | 1,352.5% | 1,063.5% | 967.2% | 672.9% | 408.9% | 648.7% | |
| -705.6% | -723.2% | -860.2% | -831.5% | -551.2% | -870.6% | -660.9% | -1,416.2% | -1,005.1% | -895.8% | -603.9% | -314.1% | -568.4% | |
| – | – | 72.1% | – | 10.7% | – | – | – | 0.0% | 1.7% | – | – | – | |
| -701.3% | -723.0% | -601.9% | -3,567.8% | -503.6% | -856.2% | -692.8% | -1,415.0% | -972.9% | -870.3% | -584.4% | -299.4% | -548.6% | |
| -30.5% | – | -48.8% | – | – | 1.7% | – | – | – | – | – | – | – | |
| -701.3% | -723.0% | -601.9% | -3,567.8% | -503.6% | -856.2% | -692.8% | -1,415.0% | -972.9% | -870.3% | -584.4% | -299.4% | -548.6% | |
| -676.8% | – | -553.1% | -3,513.2% | -485.6% | -837.0% | -672.5% | -1,390.8% | -958.9% | -861.3% | -576.3% | -295.0% | -541.4% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.